Amgen Inc. $AMGN Shares Purchased by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 290,302 shares of the medical research company’s stock after purchasing an additional 14,425 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Amgen were worth $95,022,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of AMGN. Ashton Thomas Private Wealth LLC raised its holdings in shares of Amgen by 1.1% in the fourth quarter. Ashton Thomas Private Wealth LLC now owns 95,831 shares of the medical research company’s stock valued at $31,366,000 after buying an additional 1,041 shares during the last quarter. Anchyra Partners LLC purchased a new position in shares of Amgen during the fourth quarter worth about $936,000. Aprio Wealth Management LLC grew its holdings in shares of Amgen by 80.2% during the fourth quarter. Aprio Wealth Management LLC now owns 2,986 shares of the medical research company’s stock worth $977,000 after buying an additional 1,329 shares during the last quarter. D.A. Davidson & CO. increased its position in Amgen by 2.1% in the 4th quarter. D.A. Davidson & CO. now owns 248,154 shares of the medical research company’s stock valued at $81,224,000 after acquiring an additional 5,100 shares during the period. Finally, Camelot Portfolios LLC purchased a new stake in Amgen during the 4th quarter valued at approximately $164,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN opened at $340.11 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock’s 50 day moving average is $360.16 and its two-hundred day moving average is $340.08. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The firm has a market capitalization of $183.55 billion, a PE ratio of 23.90, a P/E/G ratio of 3.60 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 22.16 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.0%. Amgen’s dividend payout ratio is presently 70.84%.

Analysts Set New Price Targets

Several analysts have commented on AMGN shares. Guggenheim upped their price objective on Amgen from $347.00 to $351.00 and gave the company a “neutral” rating in a research note on Thursday, April 9th. Daiwa Securities Group lifted their target price on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group boosted their target price on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.